Hospital Acquired Infections
Ensuring patient health, one test at a time.
Hospital Acquired Infections (HAIs), otherwise known as Healthcare-Associated Infections, are infections patients get while receiving medical treatment in healthcare facilities, such as a hospital, ambulatory surgical center, nursing home, etc.
HAIs present a major, but largely preventable, threat to patient safety. According to the CDC and the New England Journal of Medicine, in 2011, there were an estimated 722,000 instances of Hospital Acquired Infections in U.S. acute care hospitals. Of these, around 75,000 patients succumbed to these infections. While this figure is on the decline, Hardy Diagnostics shares the sentiment that anything above zero is too many.
Hardy Diagnostics is doing our part to help prevent further instances of HAIs with a range of products specifically designed to detect harmful bacteria before they infect a patient.
BCSA
Catalog no. G09
Hardy Diagnostics Burkholderia cepacia Selective Agar (BCSA) is used for the selective isolation of Burkholderia (Pseudomonas) cepacia.
HardyCHROM™ UTI
Catalog no. G313
HardyCHROM™ UTI is a non-selective chromogenic medium recommended for the cultivation, differentiation, and enumeration of urinary tract pathogens based on colony color and morphology.
HardyCHROM™ ESBL
Catalog no. G321
HardyCHROM™ ESBL is a selective and differential chromogenic medium intended for the qualitative and presumptive detection of the following from stool specimens: 1) Enterobacteriaceae that are potentially non-susceptible to ceftazidime and cefpodoxime; and 2) Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca.
HardyCHROM™ MRSA
Catalog no. G307
HardyCHROM™ MRSA is a selective and differential chromogenic medium recommended for the qualitative detection of nasal colonization by methicillin-resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings.
BCYE Agar
Catalog no. P251
Buffered Charcoal Yeast Extract (BCYE) Agar formulations are recommended for use in the cultivation and primary isolation of Legionella spp. in water and other samples suspected of harboring the bacteria.
HardyCHROM™ MRSA
Catalog no. P14
HardyCHROM™ MRSA, Contact Plate is a chromogenic medium recommended for use in the cultivation of methicillin-resistant Staphylococcus aureus (MRSA) from environmental surfaces to aid in the prevention and control of MRSA infections in health care settings.
C. diff Banana Broth™
Catalog no. K226
C. diff Banana Broth™ (Clostridium difficile Brucella Broth with Thioglycolic Acid and L-cystine or CDBB-TC) is recommended for the culture and recovery of Clostridium difficile spores and vegetative cells from environmental samples.
Cetrimide Select Agar
Catalog no. G18
Hardy Diagnostics Cetrimide Selective Agar is recommended for the selective isolation and identification of Pseudomonas aeruginosa.
AnaeroGRO™ Cycloserine-Cefoxitin Fructose Agar (CCFA)
Catalog no. AG501
Hardy Diagnostics AnaeroGro™ Cycloserine-Cefoxitin Fructose Agar (CCFA) is an enriched selective and differential medium recommended for the cultivation and isolation of Clostridium difficile from fecal specimens. C. difficile is a recognized cause of intestinal infections and pseudomembranous colitis following antibiotic therapy.
Request more information
"*" indicates required fields
I want to make sure that you know how much we appreciate how user-friendly Hardys product information is
Hardy Diagnostics understands clinical microbiology and has never disappointed us whenever we need support, even if that support is electronic.
